Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancer

Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancer - Neoadjuvant chemotherapy for BRCAness

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029433

Enrollment

Registered

2017-10-05

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Patients who have obtained consent from tis study will start neoadjuvant chemotherapy with the following 3 anti-cancer drugs every 3 weeks for a total of 4 cycles. Fluorouracil 500mg/m2 Epirubicin 10

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.Patients with primary breast cancer who indicates the neoadjuvant chemotherapy from stage 1-3 2.PS 0-1 3.normal cardiac function 4.clinical examination is normal

Exclusion criteria

Exclusion criteria: 1.Patients who have been administered moderate doses of anti-cancer drugs. 2.Patients who have been undergone gastrointestinal surgery 3.Active double cancers 4.Pregnant, lactating, possible pregnancy, having oral contraceptive 5.Patients who the investigator judged unsuitable for this trial

Design outcomes

Primary

Measure	Time frame
pathologic complete response(pCR)	—

Countries

Japan

Contacts

Public ContactSaeko Teraoka

Tokyo medical university hospital breast oncology

s_teraoka0809@yahoo.co.jp0333516141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026